Inflammatory disease and C-reactive protein in relation to therapeutic ionising radiation exposure in the US Radiologic Technologists

Mark P. Little, Michelle Fang, Jason J. Liu, Ann Marie Weideman & Martha S. Linet

Chronic inflammation underlies many autoimmune diseases, including hypothyroidism, hyperthyroidism, and rheumatoid arthritis, also type-2 diabetes and osteoarthritis. Associations have been suggested of high-dose ionising radiation exposure with type-2 diabetes and elevated levels of C-reactive protein, a marker of chronic inflammation. In this analysis we used a proportional hazards model to assess effects of radiotherapy on risks of subsequent inflammatory disease morbidity in 110,368 US radiologic technologists followed from a baseline survey (1983–1989/1994–1998) through 2008. We used a linear model to assess log-transformed C-reactive protein concentration following radiotherapy in 1326 technologists. Relative risk of diabetes increased following radiotherapy (p < 0.001), and there was a borderline significant increasing trend per treatment (p = 0.092). For osteoarthritis there was increased relative risk associated with prior radiotherapy on all questionnaires (p = 0.005), and a significant increasing trend per previous treatment (p = 0.024). No consistent increases were observed for other types of inflammatory disease (hypothyroidism, hyperthyroidism, rheumatoid arthritis) associated with radiotherapy. There was a borderline significant (p = 0.059) increasing trend with dose for C-reactive protein with numbers of prior radiotherapy treatments. Our results suggest that radiotherapy is associated with subsequent increased risk of certain inflammatory conditions, which is reinforced by our finding of elevated levels of C-reactive protein.

Chronic inflammation underlies many autoimmune diseases, including hypothyroidism, hyperthyroidism, rheumatoid arthritis, type-1 diabetes and Crohn’s disease1,2. Type-2 diabetes and osteoarthritis are not auto-immune diseases, but also have a substantially inflammatory etiology2–4. Associations have been suggested of moderate/high dose ionising radiation exposure with certain inflammatory diseases, in particular with hypothyroidism in Chernobyl 131I-exposed populations5,6, with type-2 diabetes after high-dose radiotherapy (RT) of the abdomen in adults treated for peptic ulcer7, and with type-2 diabetes in persons treated for childhood cancer8–10. However, associations of high-dose radiation exposure with other inflammatory diseases have not been demonstrated.

One of the best-known markers of systemic inflammation is C-reactive protein (CRP), which is produced by the liver in response to acute inflammation11. Since CRP is rapidly metabolized, persistently elevated levels of CRP are a marker of continuing chronic inflammation. Dose-related excess levels of CRP have been observed in the Japanese atomic-bomb survivors Life Span Study (LSS) cohort12 and in persons receiving RT13–16.

In this paper we investigated associations of several types of inflammatory disease morbidity (specifically hypothyroidism, hyperthyroidism, type-2 diabetes, rheumatoid arthritis, osteoarthritis) and CRP with previous RT exposure. We evaluated exposure response using the proxy measure of numbers of treatments or number/type of irradiated body regions determined from the questionnaires that the technologists completed.
Results

Table 1 shows that there were generally highly significant ($p < 0.001$) risks for all five morbidity endpoints associated with most of the underlying lifestyle and medical risk factors. Smoking was associated with excess risk of all outcomes except hypothyroidism and osteoarthritis. Race/ethnicity was linked to all outcomes except hyperthyroidism and rheumatoid arthritis. In consequence, all of these risk factors (sex, body mass index, smoking status, racial/ethnic group, smoking, year of birth, and duration of work) were used as adjustment factors for the analysis presented in Table 2. Additional analysis given in Supplementary Information Part B Table B2 demonstrates the additional breakdown by RT and the significant variation that was thereby introduced. Supplementary Information Part B Table B2 demonstrates that there were significant departures from the random distribution of $[\text{case vs non-case}] \times [\text{RT vs non-RT}]$ in relation to almost all the putative risk factors (sex, racial/ethnic group, birth year, attained age, smoking status, BMI) that would be expected given the marginal totals.

Table 2 demonstrates indications of increased RR of type-2 diabetes with RT recorded at $Q_1 = 1.29$ (95% CI 1.17, 1.43, $p < 0.001$). There was also a clear increasing dose response with increasing numbers of RT treatments, with RR increasing to 3.63 (95% CI 1.48, 8.88) for four treatments, and a borderline significant increasing trend per treatment, with RR/treatment $= 1.12$ (95% CI 0.99, 1.28, $p = 0.092$) (Table 2). Supplementary Information Part B Table B3 demonstrates elevated risk of diabetes with RT cancer treatment, with RR $= 1.59$ (95% CI 1.01, 2.52, $p = 0.063$). For Q1 data there was highly significant ($p < 0.001$) interaction of RT and BMI, with diabetes risk markedly elevated for those with BMI $< 18.5$ kg m$^{-2}$; there was no such significant interaction for the combined (Q1/Q2) RT data, or for number of RT treatments ($p > 0.5$) (results not shown). Supplementary Information Part B Table B3 demonstrates elevated risk of rheumatoid arthritis associated with pelvic RT, with RR $= 2.20$ (95% CI 1.04, 4.67, $p = 0.068$). For osteoarthritis, there was increased RR associated with RT at Q1/Q2 $= 1.19$ (95% CI 1.06, 1.35, $p = 0.005$). There was a significant RR/treatment trend ($p = 0.05$) for the random distribution of CRP. There was no significant departure from the random distribution of CRP for the combined (Q1/Q2) RT data, or for osteoarthritis associated with head RT, with RR $= 1.28$ (95% CI 1.05, 1.55, $p = 0.047$) and with RT treatment for non-malignant disease, with RR $= 1.25$ (95% CI 1.06, 1.48, $p = 0.013$). No consistent increases were observed for other types of inflammatory disease associated with RT. These findings were generally similar in the minimally adjusted analysis (Supplementary Information Part B Table B1).

Table 3 shows that the distribution of CRP varies statistically significantly ($p < 0.001$) by sex, race and BMI, but not markedly for any of the other variables evaluated (birth year, age at blood draw, smoking). Sex and BMI were also among the variables chosen by step-AIC for inclusion in the optimal background model for CRP, along with the other variables listed in Supplementary Information Part A Table A2. Likewise, Supplementary Information Part B Table B4 shows the distribution of CRP in relation to lifestyle and medical variables, as well as RT. Supplementary Information Part B Table B4 demonstrates that there were significant departures ($p < 0.05$) from the random distribution of CRP levels $[< 1 \text{mg/l vs } 1 - < 3 \text{mg/l vs } \geq 3 \text{mg/l}] \times [\text{RT vs non-RT}]$ in relation to sex, race, and BMI that would be expected given the marginal totals. However, there were no such significant departures for the other three variables (birth year, attained age, smoking status).

Table 4 and Fig. 1 suggest that there was a borderline significant ($p = 0.059$) increasing trend with dose for CRP with numbers of RT treatments or body areas exposed to RT procedures reported, with CRP increasing by 21.4% (95% CI -0.7, 48.5) per RT procedure.

Discussion

This large and predominantly female cohort is the first prospective cohort study to identify an association of RT with subsequent report of osteoarthritis and only the second known study to link RT in adulthood with type-2 diabetes. A potential mechanism for these associations is suggested by the marginally significant ($p = 0.059$) finding of increased levels of CRP, a marker of systemic chronic inflammation, associated with RT. There were no indications of effects of RT on other types of inflammatory disease, specifically hypothyroidism, hyperthyroidism, or rheumatoid arthritis. A novel feature of this study is examination of various type of inflammatory disease in relation to numbers of RT treatments.

There have been only four previous studies examining the relationship between type-2 diabetes and high dose RT. Kleinerman et al. found a RR of 3.79 (95% CI 1.2, 12.0) associated with >16 Gy to the pancreas in a group treated for peptic ulcer in adulthood. In a Dutch cohort of childhood cancer survivors a dose of $\geq 36$ Gy to the pancreas tail was associated with an RR of 2.43 (95% CI 1.22, 4.85). In a French-UK cohort of childhood cancer survivors, there was an excess RR of 0.61 Gy$^{-1}$ (95% CI 0.21, 1.68) associated with dose to the pancreas tail. Because doses were not estimated in our study, it is difficult to compare our risks with these studies. In another cohort of childhood cancer survivors, Meacham et al. documented an RR associated with abdominal irradiation of 3.4 (95% CI 2.3, 5.0), consistent with our estimated RR of 1.71 (95% CI 0.85, 3.47) associated with abdominal RT (Supplementary Information Part B Table B3). To the best of our knowledge, for none of the other inflammatory endpoints studied have there been assessments of the effects of prior RT.

The null findings for hypothyroidism and RT (Table 2) are consistent with the lack of dose-related prevalence in the LSS cohort, although perhaps inconsistent with the dose-related excess observed in two Chernobyl-exposed cohorts. It is likely that this apparent discrepancy is explained by the differences in type of radiation, with the current study implicitly examining external radiation from RT whereas the Chernobyl-exposed groups were exposed primarily to $^{137}$Cs, but the discrepancy may also result from the fact that in the Chernobyl-exposed groups the excess was largely restricted to sub-clinical disease, and possible differences in diagnostic criteria. The null findings for hyperthyroidism are consistent with the similarly null findings in the LSS cohort in a Chernobyl-exposed group.

There is evidence from prospective studies that elevated levels of the pro-inflammatory cytokines interleukin-6, CRP and tumor necrosis factor-$\alpha$ (TNF$\alpha$) may be associated with type-2 diabetes. There is also...
evidence of up-regulation of the anti-inflammatory interleukin-1 receptor antagonist, produced by the body in response to the pro-inflammatory interleukin-1β, before the onset of diabetes.  

The two best established risk factors for osteoarthritis are age and obesity. Experimental studies have suggested mechanisms of cartilage degradation and reduced proteoglycan synthesis. Excess occupational risks have...
also been associated with female cleaners and workers in clothing industries, male masseurs and other construction workers, and agricultural workers of both sexes, possibly related to the element of heavy manual work in these professions. Many radiologic technologists wore leaded aprons, which would impose substantial load on the joints in the lower part of the body, although it is unlikely that use of such aprons would correlate with RT. Our analysis adjusted for numbers of years worked, which suggests that at least this crude cumulative measure of joint “wear” does not explain our findings. However, purely mechanical joint loading is only part of the picture. There is a considerable body of evidence that, in obese people, even non-weight bearing joints are affected by osteoarthritis, suggesting a role for lipid metabolism, and specifically certain adipokines, in causing osteoarthritis. There is more general evidence that inflammatory cytokines such as interleukin-1, TNFα, and prostaglandin E2 play a role in rheumatoid arthritis and osteoarthritis.

In view of the inflammatory etiology of osteoarthritis, it is unsurprising that type-2 diabetes, a largely inflammatory disease, has been shown to be a risk factor (independent of BMI and age). It is also to be expected that osteoarthritis may be a risk factor for type-2 diabetes, and more generally for metabolic syndrome, of which type-2 diabetes is part. The relationship we found between RT and osteoarthritis is therefore not too surprising, given the inflammatory nature of the disease. There are indications from various case series that RT may be a risk factor for osteoarthritis, but to the best of our knowledge this has not been established in any prospective cohort.

One of the best-known markers of inflammation is CRP, which is produced by the liver in response to acute inflammation, in particular the rise in concentration of the pro-inflammatory IL-6. Dose-related excess levels of CRP have been observed in the LSS, 50–52 years after exposure, and in persons receiving RT≥16, generally sampled a much shorter period (at most weeks) after RT. A weakness of the studies of CRP associated with RT, as with our study, is that it is unclear whether it is the underlying disease for which RT is given, or the RT itself, that may be associated with elevated CRP. The finding that CRP was chronically elevated after RT is consistent with long-lasting dose-related change in CRP in the LSS cohort, although the magnitude was much greater here (Table 4, Fig. 1) and in other groups given RT, possibly a function of the likely much higher RT doses.

Adjustment for these variables had only minimal effect on risks of inflammatory disorders arising after RT; the minimally-adjusted and fully-adjusted RRs were very similar (Table 2, Supplementary Information Part B Table B1). Weights of the study include ascertainment of RT and inflammatory disorders solely by questionnaire and lack of validation by medical records. There was no information on location of osteoarthritis, in relation to the RT-treated areas. However, as discussed above, osteoarthritis is in part systemic, and so lack of locational information may be irrelevant. There is little information on timing of the RT procedures, so that these exposures could only be treated as non-time-varying in the analysis. However, the sensitivity and specificity of self-reported diagnosis of osteoarthritis in the general population are generally high, >75%34,39, while for type-2 diabetes the sensitivity and specificity are generally even higher, >80%37–40. A variety of studies, reviewed elsewhere, suggest that self-reported rheumatoid arthritis is reported with variable sensitivity and specificity, between 10–90%. A Danish study suggests that self-reported hyperthyroidism and hypothyroidism are reported with high (98%) sensitivity, although only moderate (57–67%) specificity. Recall of RT in the general population has been found to

### Table 2. Incidence of inflammatory disease following administration of radiotherapy in 110,368 U.S. radiologic technologists.

| Radiotherapy body regions received | Hypothyroidism | Hyperthyroidism | Type-2 Diabetes | Rheumatoid arthritis | Osteoarthritis |
|-----------------------------------|---------------|-----------------|-----------------|---------------------|---------------|
|                                   | RR (95% CI)   | RR (95% CI)     | RR (95% CI)     | RR (95% CI)         | RR (95% CI)   |
| All radiotherapy (Q1)             | 1.03 (0.93, 1.13) | 0.98 (0.79, 1.21) | 1.07 (0.92, 1.24) | 0.93 (0.77, 1.12) | 1.08 (0.99, 1.17) |
| Four vs None                      | 0.70 (0.17, 2.82) | 0.945           | 0.97 (0.70, 1.34) | 1.07 (0.88, 1.32) | 0.83 (0.55, 1.24) |
| One vs None                       | 1.05 (0.90, 1.22) | 0.84 (0.35, 2.03) | 1.18 (0.74, 1.87) | 0.836 (1.48, 8.88) | 1.07 (0.61, 1.71) |
| Three vs None                     | 0.91 (0.34, 2.44) | 1.58 (0.22, 11.29)| 3.63 (1.48, 8.88) | 2.04 (0.28, 14.65) | 0.80 (0.20, 3.23) |
| Continuous trend per number of treatments | 1.02 (0.91, 1.13) | 0.754           | 0.98 (0.78, 1.23) | 1.12 (0.99, 1.28) | 0.96 (0.73, 1.26) |
| Sex               | CRP mean (mg/ml) (1st quartile/median/3rd quartile) | Relative excess of CRP compared with reference level (+95% CI)b | p-valueb |
|-------------------|-----------------------------------------------|---------------------------------------------------------------|-----------|
| Female            | 5.66 (1.14/2.67/6.61)                         | 1 (=reference)                                               | <0.001    |
| Male              | 4.07 (0.96/2.03/4.42)                         | 0.76 (0.67, 0.87)                                            |           |
| Racial group      |                                               |                                                               |           |
| White             | 4.43 (0.97/2.12/5.17)                         | 1 (=reference)                                               | <0.001    |
| Black             | 6.12 (1.31/3.07/7.66)                         | 1.35 (1.19, 1.55)                                            |           |
| Asian + Pacific islander | 2.24 (0.84/1.62/3.64)                    | 0.47 (0.12, 1.83)                                            |           |
| Other/unknown     | 2.64 (1.32/1.65/3.45)                         | 0.54 (0.21, 1.41)                                            |           |
| Birth year        |                                               |                                                               |           |
| <1920             | 4.18 (1.34/2.72/5.12)                         | 1 (=reference)                                               | 0.142     |
| 1920–1929         | 4.70 (1.01/2.06/5.42)                         | 0.83 (0.49, 1.42)                                            |           |
| 1930–1939         | 5.41 (1.13/2.58/6.36)                         | 0.98 (0.59, 1.63)                                            |           |
| 1940–1949         | 5.55 (1.17/2.65/6.33)                         | 1.00 (0.60, 1.66)                                            |           |
| ≥1950             | 4.64 (0.95/2.23/5.70)                         | 0.83 (0.50, 1.38)                                            |           |
| Age at blood draw |                                               |                                                               |           |
| <50               | 5.67 (0.55/1.57/6.10)                         | 1 (=reference)                                               | 0.497     |
| 50–59             | 4.62 (1.03/2.29/5.81)                         | 1.17 (0.64, 2.13)                                            |           |
| 60–69             | 5.54 (1.11/2.56/6.28)                         | 1.33 (0.72, 2.43)                                            |           |
| 70–79             | 5.21 (1.13/2.29/6.39)                         | 1.30 (0.71, 2.38)                                            |           |
| ≥80               | 5.14 (1.13/2.25/5.35)                         | 1.22 (0.64, 2.31)                                            |           |
| Smoking           |                                               |                                                               |           |
| Not current smoker| 5.03 (1.04/2.28/6.10)                         | 1 (=reference)                                               | 0.174     |
| Missing/unknown   | 5.42 (1.27/2.38/6.54)                         | 1.14 (0.92, 1.40)                                            |           |
| Current smoker    | 4.67 (1.68/3.78/5.63)                         | 1.35 (0.91, 2.01)                                            |           |
| Body mass index (BMI) (kg/m²) at Q1 |                   |                                                               |           |
| 18.5–24.9         | 4.32 (0.91/2.05/5.31)                         | 1 (=reference)                                               | <0.001    |
| unknown           | 5.63 (1.05/2.16/6.30)                         | 1.14 (0.95, 1.35)                                            |           |
| <18.5             | 2.90 (0.82/1.64/2.78)                         | 0.74 (0.44, 1.24)                                            |           |
| 25.0–29.9         | 5.50 (1.41/2.93/6.51)                         | 1.36 (1.16, 1.60)                                            |           |
| ≥30.0             | 6.90 (1.70/4.15/10.25)                        | 1.82 (1.44, 2.30)                                            |           |

Table 3. CRP according to demographic and lifestyle factors, among 1326 US Radiologic Technologists with a usable blood draw sample. Information generally determined from the special questionnaire administered to the technologists at time of blood draw [RQ1], unless otherwise indicated – see Supplementary Information Part A Table A1. Relative excess CRP values over reference level, and p-value of significance of fit, established via fitting a linear model to the log-transformed CRP data.

Figure 1. Percentage change (+95% CI) in C-reactive protein level with number of radiotherapy treatments. Analysis is as in Table 4.
have a sensitivity of 60% or better, and specificity of 70% or better\(^{43,44}\). The population of radiologic technologists reported here was medically literate, so that self-diagnosis of osteoarthritis and type-2 diabetes and the location of RT fields should be even better than these figures would suggest. As with many occupational studies, cohort members had to survive to answer the first questionnaire. However, such selection will not necessarily bias our analysis, since everyone had to survive to answer a questionnaire, and risk was assessed conditional on that.

In summary, we found indications of increased risk of type-2 diabetes and osteoarthritis, and elevated levels of CRP associated with RT exposure. The findings for osteoarthritis are novel and in need of replication in other prospectively-evaluated cohorts. Future large prospective studies are needed with validation of RT using radiation oncology records that provide information about anatomic site and number of treatments and medical record validation of a broad range of inflammatory conditions with detailed information about onset and natural history.

### Data and Methods

#### Overview.

*Study population and follow-up.* The USRT study population and methods are described elsewhere\(^{40–45}\) and detailed information can be found online (www.radtechstudy.nci.nih.gov). Briefly, in the mid-1980s, the US National Cancer Institute, in collaboration with the University of Minnesota and the American Registry of Radiologic Technologists (ARRT), began a study of cancer incidence and mortality among 146,021 Registry of Radiologic Technologists (ARRT), began a study of cancer incidence and mortality among 146,021 (106,953 women) US radiologic technologists who were certified for at least 2 years between 1926 and 1982\(^{46}\). Annual follow-up was conducted by obtaining records of yearly re-certification with the ARRT. For technologists who did not recertify, vital status through December 31, 2008 was obtained through periodic linkage with the Social Security Administration, and for those determined or presumed to be deceased, the cause of death was obtained through linkage with the National Death Index (NDI-Plus) records.

*Data collection.* The cohort was surveyed three times between 1983 and 2005. The first questionnaire (1983–1989)(Q1) was mailed to 132,298 known-living radiologic technologists, of whom 90,305 (68%) responded. The second questionnaire (1994–1998)(Q2) was mailed to 126,628 known-living technologists, of whom 90,972 (72%) responded. Both surveys asked for detailed work history information about employment as a radiologic technologist, lifestyle and other risk factors for cancer and other chronic diseases, and personal history of therapeutic medical radiation procedures. Technologists were also queried about personal history of cancer and selected other health outcomes associated with radiation exposure in other populations. The third questionnaire (2003–2005)(Q3) was mailed to 101,694 living cohort members who had completed at least one of Q1 or Q2; 73,838 technologists (73%) responded. Q3 elicited similar information on medical outcomes as well as detailed work history. In each of the three main questionnaires, participants were asked if they had ever been diagnosed with hypothyroidism or hyperthyroidism, and in Q2 and Q3 they were asked about type-2 diabetes, rheumatoid arthritis and osteoarthritis (Supplementary Information Part B).

*Eligible populations.* 

*Questionnaire assessment component.* To be included in the current study, technologists had to have completed Q1 or Q2 and been followed through the earlier of either date of death or December 31, 2008 (the end of the study period). Of the 110,374 technologists meeting these criteria, the date of last vital status was unknown for five participants, and another individual had entry date equal to exit date; exclusion of these left an analysis dataset of 110,368 technologists. Demographic and lifestyle characteristics of the eligible population for this component are summarized in Table 1.

*CRP component.* Blood serum samples were taken from a subcohort of 1644 US radiologic technologists, selected from a random sample of the main USRT population that was enriched by inclusion of blacks and stratified by sex, age, and latitude, for a study of determinants of vitamin D\(^{49,50}\). Samples were obtained during 2008–2009, with a supplemental questionnaire (RQ1) concurrently administered. CRP was one of the determinants measured\(^{49}\). Of these 1644 technologists, 1327 (824 female) yielded detectable CRP. Methods for selecting the sample and processing biological material are described at greater length elsewhere\(^{49,50}\). One subject was removed from the dataset because the number of self-recorded body regions exposed to RT (11) substantially exceeded the

---

### Table 4.

| Number of radiotherapy treatments | Number of persons undergoing radiotherapy | Percent change in C-reactive protein from reference category (95% CI) | p-value |
|----------------------------------|------------------------------------------|-------------------------------------------------|---------|
| 0                                | 1260                                     | 0 (ref)                                         |         |
| 1                                | 56                                       | 16.5 (−13.7, 57.4)                              | 0.491\(^{a}\) |
| 2                                | 6                                        | 21.4 (−50.3, 196.5)                             |         |
| 3                                | 3                                        | 112.6 (−38.9, 639.8)                            |         |
| 4                                | 1                                        | 344.8 (−49.9, 3846.2)                           |         |

**Continuous trend per number of radiotherapy treatments**

| Number of radiotherapy treatments | Percent change in C-reactive protein from reference category (95% CI) | p-value |
|----------------------------------|-------------------------------------------------|---------|
| 0                                | 21.4 (−0.7, 48.5)                               | 0.059\(^{b}\) |

---

\(^{a}\)p-value of heterogeneity of relative risk; \(^{b}\)p-value of trend of relative risk with numbers of treatments.
maximum (of 4) in the remaining data, resulting in an analysis dataset of 1326 individuals. The demographic and clinical data associated with the blood draw participants originated from Q1 and Q2, the supplemental questionnaire administered concurrently with phlebotomy (RQ1), and a third full-length questionnaire that was mailed or administered by phone.

Outcomes selected for study. The five specific inflammatory disease outcomes selected were elicited at baseline and in the two follow-up questionnaires, as indicated above. Other inflammatory disease outcomes that technologists were asked about in follow-up, but not the baseline questionnaires, were excluded. For each morbidity endpoint, the subject had to have been free of the specified disease at study entry (as indicated by responses to questions about diagnosis of these conditions on Q1/Q2) and informative at the last questionnaire.

Exposure assessment. Questions were asked on Q1/Q2 about anatomic sites treated with RT, and additionally (a) on Q1 the first year treated and the number of treatments, and (b) on Q2 whether RT had been given by decade (<1980, 1980–1989, 1990+) and whether for cancer or other conditions.

Potential confounders. A literature review by AMW/MF suggested a number of variables potentially associated with CRP including age at blood draw, race, gender, and menopause-related variables, use of oral contraceptives, cigarette smoking, body mass index (BMI), exercise, various diseases potentially associated with an inflammatory mechanism (including inflammatory bowel disease, goiter, thyroiditis, hyperthyroidism, hypothyroidism, other thyroid disease, parathyroid disease (including hyperparathyroidism), angina, stroke, transient ischemic attacks, type-2 diabetes, Parkinson’s disease, scleroderma, etc). The complete list of variables used is given in Supplementary Information Part B Table A1.

Statistical Methods. Analysis of inflammatory disease and radiotherapy: We evaluated history of RT at baseline (Q1/Q2) and then followed the subjects for subsequent incidence of the inflammatory diseases as reported in a questionnaire after baseline. We assessed the relationship between known and suspected risk factors for the incident inflammatory diseases (Table 1) and compared the frequency of RT in those reporting and those not reporting diagnosis of the incident inflammatory disease outcomes (Supplementary Information Part B Table B2). We used Cox proportional hazards models with age as the timescale to estimate relative risks (RR) in relation to diagnosis of the incident inflammatory disease outcomes (Supplementary Information Part B Table B2). We used Cox proportional hazards models with age as the timescale to estimate relative risks (RR) in relation to numbers of years worked, because of the requirement that technologists wear leaded aprons, with the consequent loading of torso and lower limbs. For these reasons all Cox regression analyses of the inflammatory endpoints were adjusted for number of years worked [year last worked – year first worked], and by stratification for sex, year of birth, cigarette smoking at baseline, baseline BMI, and racial group, as shown in Table 2. Additional minimally-adjusted analysis is given in Supplementary Information Part B Table B1.

Analysis of CRP and radiotherapy: Measurement of CRP was undertaken in 2008–2009, 10–25 years after the baseline surveys. The primary aim of the study was to identify if there were significant changes in CRP with number of therapeutic radiation cycles by fitting a linear model to log-transformed CRP data (transformed to normalize the residuals) in relation to indicators of RT exposure. In order to determine which of the candidate variables (Supplementary Information Part A Table A1) affected CRP in this cohort, and to avoid over-fitting, the Akaike Information Criterion (AIC) was used to select the optimal variables (Supplementary Information Part A Table A2) from these. All statistical analyses were carried out using ordinary least squares, and tests were performed using analysis of variance (ANOVA) in R. Further details on statistical methods are given in Supplementary Information Part B.

Ethical approvals. Informed consent was obtained from all participants. The research protocol for the USRT cohort study of cancer and other health risks has been approved annually by the National Cancer Institute Special Studies Institution Review Board (SSIRB; Protocol OH97-C-N053) and the University of Minnesota Human Research Protection Program Institution Review Board (Study number 8005M02489). All methods were performed in accordance with the relevant guidelines and regulations of the National Institutes of Health and the University of Minnesota.

Data Availability
The data used is available from the principal author upon request.

References
1. Lacka, K. & Maciejewski, A. Rare thyroid non-neoplastic diseases. Thyroid Res 8, 5, https://doi.org/10.1186/s13044-015-0017-3 (2015).
2. Mohamed-Ali, H. Influence of interleukin-1β, tumour necrosis factor alpha and prostaglandin E2 on chondrogenesis and cartilage matrix breakdown in vitro. Rheumatol Int 14, 191–199 (1995).
3. Aspen, R. M., Scheven, B. A. & Hutchison, J. D. Osteoarthritis as a systemic disorder including stromal cell differentiation and lipid metabolism. Liver 357, 1118–1120, https://doi.org/10.1016/S0140-6736(00)04264-1 (2001).
43. Clegg, L. X. et al. Comparison of self-reported initial treatment with medical records: results from the Prostate Cancer Outcomes Study. Am J Epidemiol 154, 582–587 (2001).
44. Kemp, A. et al. Ascertaining invasive breast cancer cases: the validity of administrative and self-reported data sources in Australia. BMC Med Res Methodol 13, 17, https://doi.org/10.1186/1471-2288-13-17 (2013).
45. Doody, M. M., Mandel, J. S., Lubin, J. H. & Boice, J. D., Jr. Mortality among United States radiologic technologists, 1926-90. Cancer Causes & Control 9, 67–75 (1998).
46. Sigurdson, A. J. et al. Cancer incidence in the US radiologic technologists health study. 1983-1998. Cancer 97, 3080–3089, https://doi.org/10.1002/cncr.11444 (2003).
47. Simon, S. L. et al. Radiation organ doses received in a nationwide cohort of U.S. radiologic technologists: methods and findings. Radiat Res 182, 507–528, https://doi.org/10.1667/RR13542.1 (2014).
48. Mohan, A. K. et al. Cancer and other causes of mortality among radiologic technologists in the United States. Int J Cancer 103, 259–267, https://doi.org/10.1002/ijc.10811 (2003).
49. Liu, J. J. et al. Relationship between plasma 25-hydroxyvitamin D and leucocyte telomere length by sex and race in a US study. Br J Nutr 116, 953–960, https://doi.org/10.1017/S0007114516002075 (2016).
50. Freedman, D. M. et al. Sunlight and other determinants of circulating 25-hydroxyvitamin D levels in black and white participants in a nationwide U.S. study. Am J Epidemiol 177, 180–192, https://doi.org/10.1093/aje/kws223 (2013).
51. Manji, N. et al. Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype. J Clin Endocrinol Metab 91, 4873–4880, https://doi.org/10.1210/jc.2006-1402 (2006).
52. Knudsen, N. et al. Risk factors for goiter and thyroid nodules. Thyroid 12, 879–888, https://doi.org/10.1089/10507250276106502 (2002).
53. Fukata, S., Kuma, K. & Sugewara, M. Relationship between cigarette smoking and hypothyroidism in patients with Hashimoto’s thyroiditis. J Endocrinol Investigation 19, 607–612, https://doi.org/10.1007/BF03349026 (1996).
54. Will, J. C., Galuska, D. A., Ford, E. S., Mokdad, A. & Calle, E. E. Cigarette smoking and diabetes mellitus: evidence of a positive association from a large prospective cohort study. Int J Epidemiol 30, 540–546 (2001).
55. Symmons, D. P. M. et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum 40, 1955–1961, https://doi.org/10.1002/art.178041106 (1997).
56. Mokdad, A. H. et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289, 76–79 (2003).
57. King, L. K., March, L. & Anandacoomarasamy, A. Obesity & osteoarthritis. (eds B. N. Petrov & F. Czáki) 267–281 (Akadémiai Kiadó, Budapest, 1973).
58. Haffner, S. M. Epidemiology of type 2 diabetes: risk factors. Diabetes Care 21 (Suppl 3), C3–6 (1998).
59. Cox, D. R. Regression models and life-tables. J Royal Stat Soc Series B 34, 187–220 (1972).
60. B: A language and environment for statistical computing, version 3.4.4. www.r-project.org (R Foundation for Statistical Computing, Vienna, Austria, 2018).
61. McCullagh, P. & Nelder, J. A. Generalized Linear Models, Second Edition. In Monographs on statistics and applied probability 37 1-526 (Chapman and Hall/CRC, Boca Raton, FL, 1989).
62. Akaike, H. Information theory and an extension of the maximum likelihood principle. In 2nd International Symposium on Information Theory (eds B. N. Petrov & F. Czáki) 267–281 (Akadémiai Kiadó, Budapest, 1973).
63. Akaike, H. Likelihood of a model and information criteria. J. Econometrics 16, 3–14 (1981).
64. Rao, C. R. Linear statistical inference and its applications. 2nd edition. (John Wiley & Sons, Inc, 2002).

Acknowledgements
The authors are grateful for the detailed and helpful comments of the referee, also to the radiologic technologists who participated in the USRT Study; Jerry Reid of the ARRT for continued support of this study and Diane Kampa, Allison Iwan, and Richard Hoffbeck of the University of Minnesota for study management, data collection, and data management. This work is supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics.

Author Contributions
M.P.L., A.M.W. and M.S.L. conceived and designed the study. M.P.L., A.M.W., J.J.L. and M.S.L. were responsible for acquisition of data. M.P.L. and A.M.W. produced an analytical plan. M.P.L., A.M.W. and M.F. were responsible for data analysis. M.P.L., M.S.L., A.M.W., J.J.L. and M.F. interpreted the results. M.P.L. and A.M.W. produced a first draft of the manuscript, and all authors provided intellectual input. M.P.L. and M.S.L. are guarantors.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-41129-w. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019